uniQure reports Q2 loss of $37.7M; FDA agrees on AMT-130 BLA pathway for Q1 2026 submission

uniQure N.V.

2025-Q2 EPS reported -$1.49 revenue$6,829,000

Revenue $5.3M, down from $11.1M YoY; net loss $37.7M ($0.69/share).
FDA alignment on SAP and CMC for AMT-130 BLA; topline three-year data in Sept 2025.
AMT-260 first patient showed 92% seizure reduction at 5 months with no serious AEs.
Cash $377M expected to fund operations into H2 2027.
Appointed Kylie O’Keefe as Chief Customer and Strategy Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.